Bubs Australia Limited
BUB.ASXConsumer Staples
Manufacturer of infant milk formula.
Market Data
$0.092
-0.0%$84.0M
22.2x
$0.004
0.00%
-0.3%
Latest Earnings
Bubs Australia - Half Year Results Commentary
27 February 2026
Bubs Australia delivered a strong 1HY26 result with group revenue up 14% to $55.5M and underlying EBITDA surging to $4.4M (from $0.5M pcp), driven primarily by 48% growth in the US market. Management upgraded FY26 guidance to revenue of $120–$125M and EBITDA of $4.0–$6.0M, though gross margin compressed 1 percentage point to 48% and negative operating cash flow reflects strategic inventory build to support growth. Key points: Underlying EBITDA surged 780% to $4.4M, demonstrating operational leverage and improving profitability; US revenue growth of 48% to $34.2M shows strong market momentum and retail expansion driving category growth; Strong cash position of $9.9M plus $20M undrawn facilities provides liquidity for working capital and growth initiatives
Recent Announcements
FY26 Trading Update
Bubs Australia Limited (ASX: BUB) released an FY26 trading update projecting revenue of $105-115 million with reported EBITDA of approximately -$2 million to +$2 million, impacted by regulatory changes, supply constraints, and geopolitical disruption, though underlying EBITDA is expected at $4-8 million with continued USA expansion and FDA review progressing positively.
Bubs Australia - Half Year Results Presentation
Bubs Australia Limited reported 1H FY26 results with revenue of $55.5M (up 40%), gross profit of $26.6M (48% margin), and underlying EBITDA of $4.4M, driven by strong USA market growth of 48% and strategic investments in high-margin markets; the company upgraded FY26 guidance to $120-125M revenue and $9-11M underlying EBITDA.
Bubs Australia - Half Year Results Commentary
Bubs Australia delivered a strong 1HY26 result with group revenue up 14% to $55.5M and underlying EBITDA surging to $4.4M (from $0.5M pcp), driven primarily by 48% growth in the US market. Management upgraded FY26 guidance to revenue of $120–$125M and EBITDA of $4.0–$6.0M, though gross margin compressed 1 percentage point to 48% and negative operating cash flow reflects strategic inventory build to support growth. Key points: Underlying EBITDA surged 780% to $4.4M, demonstrating operational leverage and improving profitability; US revenue growth of 48% to $34.2M shows strong market momentum and retail expansion driving category growth; Strong cash position of $9.9M plus $20M undrawn facilities provides liquidity for working capital and growth initiatives
Bubs Australia - Half Year Report and Appendix 4D
Bubs Australia delivered H1 FY2026 revenue of $55.5M (+14% YoY), driven by strong 48% US growth, though net profit halved to $1.8M (-50%) due to higher finance costs and one-time finance income comparisons. The company maintains gross margins of 48% amid premium positioning, while managing a major inventory restocking and portfolio simplification, with FDA enforcement discretion confirmed for continued US market access. Key points: Strong US revenue growth of 48% to $34.2M, reflecting major retailer wins, expanded store count and multiple facings, positioning US as largest and most profitable market; Gross margin maintained at 48% despite inflationary pressures, airfreight and tariff charges, reflecting premium brand positioning and improved inventory/channel optimisation; EBITDA improved dramatically to $3.0M from $0.5M (+453%), though EBIT growth of 1364% reflects comparatively low prior period base
Get real-time alerts for BUB
Receive AI-powered earnings summaries and instant notifications when Bubs Australia Limited releases results.
Register Free